STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,884 | -67.4% | 20,275 | -12.2% | 0.00% | – |
| Q2 2023 | $245,351 | +109.2% | 23,081 | +64.0% | 0.00% | – |
| Q1 2023 | $117,262 | -13.8% | 14,077 | -4.5% | 0.00% | – |
| Q4 2022 | $136,032 | +189.4% | 14,738 | +299.2% | 0.00% | – |
| Q3 2022 | $47,000 | -95.7% | 3,692 | -92.9% | 0.00% | – |
| Q1 2022 | $1,093,000 | +5.3% | 51,941 | +20.0% | 0.00% | – |
| Q4 2021 | $1,038,000 | +24.3% | 43,277 | +31.9% | 0.00% | – |
| Q3 2021 | $835,000 | +483.9% | 32,813 | +673.5% | 0.00% | – |
| Q2 2021 | $143,000 | -92.1% | 4,242 | -90.8% | 0.00% | – |
| Q1 2021 | $1,799,000 | +32.7% | 46,315 | +111.5% | 0.00% | – |
| Q4 2020 | $1,356,000 | +1256.0% | 21,900 | +400.0% | 0.00% | – |
| Q1 2020 | $100,000 | -61.4% | 4,380 | -52.1% | 0.00% | – |
| Q4 2019 | $259,000 | +97.7% | 9,149 | +50.6% | 0.00% | – |
| Q3 2019 | $131,000 | +197.7% | 6,074 | +299.6% | 0.00% | – |
| Q2 2019 | $44,000 | – | 1,520 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |